Stellar Biotechnologies Stock Price, News & Analysis (NASDAQ:SBOT)

$1.08 0.02 (1.89 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$1.06
Today's Range$1.07 - $1.11
52-Week Range$1.05 - $3.00
Volume10,800 shs
Average Volume53,827 shs
Market Capitalization$12.2 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

About Stellar Biotechnologies (NASDAQ:SBOT)

Stellar Biotechnologies logoStellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:SBOT
  • CUSIP: N/A
  • Web: stellarbiotechnologies.com
Debt:
  • Current Ratio: 19.31%
  • Quick Ratio: 18.98%
Sales & Book Value:
  • Annual Sales: $1.27 million
  • Price / Sales: 8.95
  • Book Value: $1.21 per share
  • Price / Book: 0.89
Profitability:
  • Trailing EPS: ($0.51)
  • Net Income: ($5,020,000.00)
  • Net Margins: -1,025.65%
  • Return on Equity: -49.68%
  • Return on Assets: -47.30%
Misc:
  • Employees: 23
  • Outstanding Shares: 10,520,000
 
Frequently Asked Questions for Stellar Biotechnologies (NASDAQ:SBOT)

What is Stellar Biotechnologies' stock symbol?

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies, Inc. (NASDAQ:SBOT) issued its earnings results on Tuesday, May, 9th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.33 million. Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%. View Stellar Biotechnologies' Earnings History.

When will Stellar Biotechnologies make its next earnings announcement?

Stellar Biotechnologies is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Stellar Biotechnologies.

Where is Stellar Biotechnologies' stock going? Where will Stellar Biotechnologies' stock price be in 2017?

1 equities research analysts have issued 12-month price objectives for Stellar Biotechnologies' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Stellar Biotechnologies' share price to reach $4.00 in the next year. View Analyst Ratings for Stellar Biotechnologies.

Who are some of Stellar Biotechnologies' key competitors?

Who are Stellar Biotechnologies' key executives?

Stellar Biotechnologies' management team includes the folowing people:

  • Frank R. Oakes, Chairman of the Board, President, Chief Executive Officer (Age 65)
  • Kathi Niffenegger CPA, Chief Financial Officer, Secretary (Age 58)
  • Gregory T. Baxter Ph.D., Executive Vice President - Corporate Development (Age 57)
  • Tessie Mary Che Ph.D., Director (Age 65)
  • Paul Chun, Director
  • Daniel E. Morse Ph.D., Director (Age 74)
  • Charles Olson, Director
  • David L. Hill Ph.D., Independent Director (Age 65)

How do I buy Stellar Biotechnologies stock?

Shares of Stellar Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stellar Biotechnologies' stock price today?

One share of Stellar Biotechnologies stock can currently be purchased for approximately $1.08.

How big of a company is Stellar Biotechnologies?

Stellar Biotechnologies has a market capitalization of $12.2 million and generates $1.27 million in revenue each year. The biotechnology company earns ($5,020,000.00) in net income (profit) each year or ($0.51) on an earnings per share basis. Stellar Biotechnologies employs 23 workers across the globe.

How can I contact Stellar Biotechnologies?

Stellar Biotechnologies' mailing address is 332 E Scott St, PORT HUENEME, CA 93041-2939, United States. The biotechnology company can be reached via phone at +1-805-4882800 or via email at [email protected]


MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Stellar Biotechnologies (NASDAQ:SBOT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (270.37% upside)
Consensus Price Target History for Stellar Biotechnologies (NASDAQ:SBOT)
Price Target History for Stellar Biotechnologies (NASDAQ:SBOT)
Analysts' Ratings History for Stellar Biotechnologies (NASDAQ:SBOT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/2/2016Maxim GroupLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Stellar Biotechnologies (NASDAQ:SBOT)
Earnings by Quarter for Stellar Biotechnologies (NASDAQ:SBOT)
Earnings History by Quarter for Stellar Biotechnologies (NASDAQ SBOT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017($0.11)N/AView Earnings Details
8/9/2017Q3 2017($0.12)($0.12)$0.34 million$0.02 millionViewN/AView Earnings Details
5/9/2017Q2 2017($0.15)($0.11)$0.33 million$0.06 millionViewN/AView Earnings Details
2/6/2017Q1 2017($0.10)($0.15)$0.31 million$0.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stellar Biotechnologies (NASDAQ:SBOT)
2017 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stellar Biotechnologies (NASDAQ:SBOT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stellar Biotechnologies (NASDAQ SBOT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Stellar Biotechnologies (NASDAQ:SBOT)
Latest Headlines for Stellar Biotechnologies (NASDAQ SBOT)
Source:
DateHeadline
Should You Buy Stellar Biotechnologies Inc (SBOT) Now?Should You Buy Stellar Biotechnologies Inc (SBOT) Now?
finance.yahoo.com - October 18 at 1:42 AM
SBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018SBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018
finance.yahoo.com - September 6 at 8:00 AM
Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:22 AM
Stellar Biotechnologies, Inc. (SBOT) Releases Quarterly  Earnings Results, Hits EstimatesStellar Biotechnologies, Inc. (SBOT) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - August 10 at 11:28 PM
Stellar Biotechnologies Reports Third Quarter 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - August 10 at 8:20 PM
Stellar Biotechnologies Reports Third Quarter 2017 Financial ResultsStellar Biotechnologies Reports Third Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:41 AM
Stellar Biotechnologies, Inc. (NASDAQ:SBOT) to Release Earnings on MondayStellar Biotechnologies, Inc. (NASDAQ:SBOT) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 11:40 AM
Stellar Biotechnologies Expands Operations Team - PR Newswire (press release)Stellar Biotechnologies Expands Operations Team - PR Newswire (press release)
www.prnewswire.com - June 8 at 3:00 AM
Stellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 11:02 AM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters toSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
biz.yahoo.com - March 29 at 8:32 AM
Stellar Biotechnologies (SBOT) to Sell Immunogen & Vaccine Technology to MatrivaxStellar Biotechnologies (SBOT) to Sell 'Immunogen & Vaccine Technology' to Matrivax
www.streetinsider.com - March 13 at 7:24 PM
Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine TechnologyStellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology
us.rd.yahoo.com - March 13 at 7:24 PM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, FinanSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Finan
biz.yahoo.com - March 13 at 7:24 PM
Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)
www.prnewswire.com - March 2 at 1:02 AM
Amaran Biotechnology Selects Stellar KLH for Cancer VaccinesAmaran Biotechnology Selects Stellar KLH for Cancer Vaccines
us.rd.yahoo.com - March 1 at 10:06 AM
Stellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - February 7 at 8:08 AM
8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes
us.rd.yahoo.com - February 7 at 12:53 AM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - December 14 at 10:01 PM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, FinancialSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial
biz.yahoo.com - December 9 at 7:36 PM

Social Media

Financials

Chart

Stellar Biotechnologies (NASDAQ SBOT) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.